Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PDE5A | O76074 | 2/20 | 0.43 |
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | NCF1 | P14598 | 1/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29420473 | 0.99 | HRH4 (0.49) | HRH4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21796408 | 0.99 | HRH4 (0.49) | HRH4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| Ezurpimtrostat SCHEMBL29696480 | 0.93 | HRH4 (0.44) | HRH4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21796410 | 0.93 | HRH4 (0.44) | HRH4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| Ezurpimtrostat SCHEMBL17713568 | 0.93 | HRH4 (0.44) | HRH4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL21796430 | 0.93 | HRH4 (0.44) | HRH4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| Ezurpimtrostat SCHEMBL17713547 | 0.92 | HRH4 (0.43) | HRH4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21796379 | 0.92 | HRH4 (0.43) | HRH4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL21796399 | 0.92 | HRH4 (0.43) | HRH4KDM4EALDH1A1HPGDSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29420470 | 0.92 | HRH4 (0.43) | HRH4KDM4EALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2022-03-01 | — | — | US | claimed |
| EP-3846814-A1 | SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES | Genoscience Pharma (FR) | 2021-07-14 | — | — | EP | claimed |
| CN-112912081-A | Substituted 2, 4-diamino-quinolines as novel agents for fibrosis, autophagy and cathepsin B (CTSB), L (CTSL) and D (CTSD) related diseases | 基因科学医药公司 | 2021-06-04 | — | — | CN | claimed |
| US-20200079781-A1 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2020-03-12 | — | — | US | claimed |
| EP-3620164-A1 | SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES | Genoscience Pharma SAS (FR) | 2020-03-11 | — | — | EP | claimed |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2022-03-01 | — | — | US | disclosed |
| EP-3846814-A1 | SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES | Genoscience Pharma (FR) | 2021-07-14 | — | — | EP | disclosed |
| CN-112912081-A | Substituted 2, 4-diamino-quinolines as novel agents for fibrosis, autophagy and cathepsin B (CTSB), L (CTSL) and D (CTSD) related diseases | 基因科学医药公司 | 2021-06-04 | — | — | CN | disclosed |
| US-20200079781-A1 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | GENOSCIENCE PHARMA (FR) | 2020-03-12 | — | — | US | disclosed |
| EP-3620164-A1 | SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES | Genoscience Pharma SAS (FR) | 2020-03-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200079781-A1 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | CTSB, CTSD, CTSA | HRH4 652/4885KDM4E 2165/4885ALDH1A1 2635/4885 |
| US-11261189-B2 | Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases | CTSB, CTSD, CTSA | HRH4 652/4885KDM4E 2165/4885ALDH1A1 2635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.